Trident Lifeline Ltd
Incorporated in 2014, Trident Lifeline Ltd manufactures and sells pharmaceuticals
products[1]
- Market Cap ₹ 320 Cr.
- Current Price ₹ 268
- High / Low ₹ 328 / 237
- Stock P/E 16.5
- Book Value ₹ 67.8
- Dividend Yield 0.00 %
- ROCE 18.1 %
- ROE 20.0 %
- Face Value ₹ 10.0
Pros
- Company is expected to give good quarter
- Promoter holding has increased by 1.01% over last quarter.
- Company's working capital requirements have reduced from 208 days to 144 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Earnings include an other income of Rs.9.52 Cr.
- Promoter holding has decreased over last 3 years: -5.74%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|
| 22 | 32 | 45 | 87 | 115 | |
| 19 | 25 | 36 | 72 | 89 | |
| Operating Profit | 3 | 6 | 8 | 15 | 26 |
| OPM % | 12% | 20% | 18% | 17% | 22% |
| 1 | 1 | 2 | 8 | 10 | |
| Interest | 0 | 0 | 1 | 4 | 5 |
| Depreciation | 0 | 0 | 1 | 5 | 8 |
| Profit before tax | 3 | 7 | 9 | 14 | 23 |
| Tax % | -32% | 8% | 32% | 23% | |
| 4 | 6 | 6 | 10 | 19 | |
| EPS in Rs | 4.94 | 5.24 | 5.51 | 10.22 | 16.68 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 59% |
| TTM: | 93% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 44% |
| TTM: | 90% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 20% |
| 1 Year: | 12% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 18% |
| Last Year: | 20% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 8 | 12 | 12 | 12 | 12 |
| Reserves | -3 | 34 | 41 | 53 | 69 |
| 2 | 8 | 18 | 54 | 59 | |
| 7 | 9 | 16 | 37 | 47 | |
| Total Liabilities | 14 | 63 | 87 | 156 | 187 |
| 1 | 3 | 21 | 44 | 46 | |
| CWIP | 0 | 5 | 4 | 2 | 2 |
| Investments | 0 | 3 | 4 | 11 | 9 |
| 12 | 51 | 58 | 99 | 130 | |
| Total Assets | 14 | 63 | 87 | 156 | 187 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| -0 | -19 | 2 | -10 | |
| -0 | -10 | -20 | -14 | |
| 1 | 42 | 11 | 20 | |
| Net Cash Flow | 0 | 14 | -7 | -4 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 83 | 139 | 110 | 116 |
| Inventory Days | 95 | 129 | 156 | 226 |
| Days Payable | 134 | 87 | 94 | 119 |
| Cash Conversion Cycle | 44 | 182 | 173 | 224 |
| Working Capital Days | 49 | 275 | 205 | 144 |
| ROCE % | 23% | 15% | 18% |
Insights
In beta| Mar 2021 | Mar 2022 | Sep 2023 | Jun 2025 | |
|---|---|---|---|---|
| Revenue Break-up: Export % ・Standalone data |
|
|||
| Consolidated Manufacturing Capacity: Capsules Million per month |
||||
| Consolidated Manufacturing Capacity: Tablets Million per month |
||||
| Countries presence globally Number |
||||
| Export market product registrations in process Number |
||||
| Export market products registered Number |
||||
| Number of Registered Brands (Trademarks) Number |
||||
| Team Size (Employees) Number |
||||
| Total Products in Portfolio / Product Applications Number |
||||
| Consolidated Manufacturing Capacity: Injectables Million per month |
||||
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Acquisition
1d - Trident Mediquip private placement; Trident Lifeline stake falls 60.04%→57.34%.
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 23 Feb
-
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
23 Feb - Promoter trust acquired 1,200 shares (0.01%); holdings 833,966 shares (6.99%), dated 23-Feb-2026.
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 16 Feb
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 3 Feb
Annual reports
Concalls
-
Jan 2026TranscriptAI SummaryPPT
-
Nov 2025TranscriptAI SummaryPPT
-
Jul 2025TranscriptAI SummaryPPT
-
Oct 2024TranscriptAI SummaryPPT
-
Jul 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Nov 2023TranscriptAI SummaryPPT
-
Jul 2023TranscriptAI SummaryPPT
-
May 2023TranscriptAI SummaryPPT
-
Jan 2023TranscriptAI SummaryPPT
Business Overview:[1]
TFL is a pharmaceutical Company with business operations spanning formulations under its own brands, loan licence model and contract manufacturing model.
a) Pharmaceutical formulations export:
Company has a presence in 40 countries, including African, Latin America, and East
Asian countries, with ~945 registered export market products, and ~2016 export market products are under registration
b) Contract manufacturing:
Company follows an Asset-light third-party contract manufacturing model thus entailing limited direct investment in manufacturing capacities